Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pluristem Life Systems has announced plans to change its business strategy. Instead of working towards the goal of licensing out the use of its proprietary bioreactor-enabling technology, the company plans to develop cell therapy products that can be marketed on a for-sale basis.
Subscribe to our email newsletter
Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. The potential of the bone marrow transplantation market is currently estimated at an annual expenditures of $5 billion and the cardiovascular market for cell-based products is estimated to exceed $30 billion, according to research conducted at Germany’s Fraunhofer institute.
Pluristem’s R&D program is currently focused on advancing the company’s cell expansion technology, which has the unique ability to mimic different naturally-occurring physiological environments.
“My belief is that aiming towards marketing actual cell therapy products, rather than towards only developing the enabling tools for the production of cell products will provide Pluristem with added value,” commented Zami Aberman, Pluristem president & CEO. “The market for cell-based products is enormous and only the tip of the iceberg has until now been uncovered.”